360 related articles for article (PubMed ID: 26041880)
1. MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC).
Casadevall D; Gimeno J; Clavé S; Taus Á; Pijuan L; Arumí M; Lorenzo M; Menéndez S; Cañadas I; Albanell J; Serrano S; Espinet B; Salido M; Arriola E
Oncotarget; 2015 Jun; 6(18):16215-26. PubMed ID: 26041880
[TBL] [Abstract][Full Text] [Related]
2. Correlation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.
Dziadziuszko R; Wynes MW; Singh S; Asuncion BR; Ranger-Moore J; Konopa K; Rzyman W; Szostakiewicz B; Jassem J; Hirsch FR
J Thorac Oncol; 2012 Feb; 7(2):340-7. PubMed ID: 22237262
[TBL] [Abstract][Full Text] [Related]
3. Alterations of MET Gene Copy Number and Protein Expression in Primary Non-Small-Cell Lung Cancer and Corresponding Nodal Metastases.
Tran TN; Selinger CI; Kohonen-Corish MR; McCaughan B; Kennedy C; O'Toole SA; Cooper WA
Clin Lung Cancer; 2016 Jan; 17(1):30-8.e1. PubMed ID: 26395411
[TBL] [Abstract][Full Text] [Related]
4. MET gene copy number gain is an independent poor prognostic marker in Korean stage I lung adenocarcinomas.
Jin Y; Sun PL; Kim H; Seo AN; Jheon S; Lee CT; Chung JH
Ann Surg Oncol; 2014 Feb; 21(2):621-8. PubMed ID: 24212721
[TBL] [Abstract][Full Text] [Related]
5. ROS1 copy number alterations are frequent in non-small cell lung cancer.
Clavé S; Gimeno J; Muñoz-Mármol AM; Vidal J; Reguart N; Carcereny E; Pijuan L; Menéndez S; Taus Á; Mate JL; Serrano S; Albanell J; Espinet B; Arriola E; Salido M
Oncotarget; 2016 Feb; 7(7):8019-28. PubMed ID: 26783962
[TBL] [Abstract][Full Text] [Related]
6. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas.
Tsuta K; Kozu Y; Mimae T; Yoshida A; Kohno T; Sekine I; Tamura T; Asamura H; Furuta K; Tsuda H
J Thorac Oncol; 2012 Feb; 7(2):331-9. PubMed ID: 22198430
[TBL] [Abstract][Full Text] [Related]
7. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing.
Jurmeister P; Lenze D; Berg E; Mende S; Schäper F; Kellner U; Herbst H; Sers C; Budczies J; Dietel M; Hummel M; von Laffert M
Lung Cancer; 2015 Feb; 87(2):122-9. PubMed ID: 25534130
[TBL] [Abstract][Full Text] [Related]
8. High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.
Go H; Jeon YK; Park HJ; Sung SW; Seo JW; Chung DH
J Thorac Oncol; 2010 Mar; 5(3):305-13. PubMed ID: 20107422
[TBL] [Abstract][Full Text] [Related]
9. Preferential Localization of MET Expression at the Invasion Front and in Spreading Cells Through Air Spaces in Non-Small Cell Lung Carcinomas.
Lapère C; Cortot AB; Grégoire V; Cockenpot V; Tulasne D; Copin MC
Am J Surg Pathol; 2017 Mar; 41(3):414-422. PubMed ID: 28098570
[TBL] [Abstract][Full Text] [Related]
10. MET amplification, protein expression, and mutations in pulmonary adenocarcinoma.
Park S; Koh J; Kim DW; Kim M; Keam B; Kim TM; Jeon YK; Chung DH; Heo DS
Lung Cancer; 2015 Dec; 90(3):381-7. PubMed ID: 26791796
[TBL] [Abstract][Full Text] [Related]
11. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients.
Park S; Choi YL; Sung CO; An J; Seo J; Ahn MJ; Ahn JS; Park K; Shin YK; Erkin OC; Song K; Kim J; Shim YM; Han J
Histol Histopathol; 2012 Feb; 27(2):197-207. PubMed ID: 22207554
[TBL] [Abstract][Full Text] [Related]
12. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
13. c-MET Overexpression as a Poor Predictor of MET Amplifications or Exon 14 Mutations in Lung Sarcomatoid Carcinomas.
Mignard X; Ruppert AM; Antoine M; Vasseur J; Girard N; Mazières J; Moro-Sibilot D; Fallet V; Rabbe N; Thivolet-Bejui F; Rouquette I; Lantuejoul S; Cortot A; Saffroy R; Cadranel J; Lemoine A; Wislez M
J Thorac Oncol; 2018 Dec; 13(12):1962-1967. PubMed ID: 30149144
[TBL] [Abstract][Full Text] [Related]
14. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Tong JH; Yeung SF; Chan AW; Chung LY; Chau SL; Lung RW; Tong CY; Chow C; Tin EK; Yu YH; Li H; Pan Y; Chak WP; Ng CS; Mok TS; To KF
Clin Cancer Res; 2016 Jun; 22(12):3048-56. PubMed ID: 26847053
[TBL] [Abstract][Full Text] [Related]
15. Soluble c-Met Levels Correlated With Tissue c-Met Protein Expression in Patients With Advanced Non-Small-Cell Lung Cancer.
Gao HF; Li AN; Yang JJ; Chen ZH; Xie Z; Zhang XC; Su J; Lou NN; Yan HH; Han JF; Wu YL
Clin Lung Cancer; 2017 Jan; 18(1):85-91. PubMed ID: 27461774
[TBL] [Abstract][Full Text] [Related]
16. p95HER2 truncated form in resected non-small cell lung cancer.
Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
[TBL] [Abstract][Full Text] [Related]
17. Loss of phosphatase and tensin homolog protein expression is an independent poor prognostic marker in lung adenocarcinoma.
Yanagawa N; Leduc C; Kohler D; Saieg MA; John T; Sykes J; Yoshimoto M; Pintilie M; Squire J; Shepherd FA; Tsao MS
J Thorac Oncol; 2012 Oct; 7(10):1513-21. PubMed ID: 22982652
[TBL] [Abstract][Full Text] [Related]
18. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
[TBL] [Abstract][Full Text] [Related]
19. MET Amplification (MET/CEP7 Ratio ≥ 1.8) Is an Independent Poor Prognostic Marker in Patients With Treatment-naive Non-Small-cell Lung Cancer.
Yin W; Cheng J; Tang Z; Toruner G; Hu S; Guo M; Robinson M; Medeiros LJ; Tang G
Clin Lung Cancer; 2021 Jul; 22(4):e512-e518. PubMed ID: 33288441
[TBL] [Abstract][Full Text] [Related]
20. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances.
Cabillic F; Gros A; Dugay F; Begueret H; Mesturoux L; Chiforeanu DC; Dufrenot L; Jauffret V; Dachary D; Corre R; Lespagnol A; Soler G; Dagher J; Catros V; Le Calve M; Merlio JP; Belaud-Rotureau MA
J Thorac Oncol; 2014 Mar; 9(3):295-306. PubMed ID: 24518086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
